Selmod is based in Basel, Switzerland life science cluster. This unique opportunity contributes first-in-class drug candidates to combat multi-resistant infections. Focus on high-revenue patients in hospital settings, to provide 2nd-line and last-resort treatments where first-line treatments have failed due to resistance. A disruptive approach to developing antibiotics with new dual modes of action addresses the need to overcome existing resistance mechanisms to current therapeutics. All are successfully proven in in-vivo animal infection studies. Market projections for the three assets – SLM500, SLM100, and SLM300 – are promising, with an estimated total available market (TAM) of over $9 billion in 2022. Aim to capture a significant share of this market within the first few years after market entry. Experienced leadership team with a proven track record in developing clinical candidates for big pharma. Use of funds to provide 3 IND-enabling candidates (SLM500) and 6 lead-optimized candidates in POC.
